Drug Profile
Bisnorcymserine - Annovis Bio
Alternative Names: ANVS-301; Bisnorcymcerine; BNCLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator National Institute on Aging; National Institutes of Health (USA)
- Developer Annovis Bio; Cenomed BioSciences; National Institute on Aging; National Institutes of Health (USA)
- Class Antidementias; Phenylcarbamates; Small molecules
- Mechanism of Action Amyloid beta-protein precursor inhibitors; Butyrylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
- Discontinued Poisoning
Most Recent Events
- 24 Apr 2022 Bisnorcymserine is still in phase I development in Alzheimer's disease (In the elderly, In volunteers) in USA (PO, Capsule)
- 24 Apr 2022 Phase-I clinical trials in Alzheimer's disease (In the elderly, In volunteers) in USA (PO)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In volunteers) in USA (PO, Capsule)